The Importance of SGLT-2 Inhibitors As Both the Prevention and the Treatment of Diabetic Cardiomyopathy

Overview

Journal Antioxidants (Basel)

Date 2022 Dec 23

PMID 36552708

Authors

Klaudia Kowalska

Piotr Wilczopolski

Dominika Bulawska

Ewelina Mlynarska

Jacek Rysz

Beata Franczyk

Affiliations

Soon will be listed here.

Abstract

According to the 2021 report of the International Diabetes Federation (IDF), there have been approximately 573 million cases of type 2 diabetes mellitus (T2DM) among adults, which sets the disease as a major concern in healthcare worldwide. The development of T2DM is strongly promoted by unhealthy lifestyle factors associated with urbanization and western civilization. The disease is associated with a broad list of systemic complications that can result in premature death, disability and significantly reduced quality of life. The most dramatic in their consequences are cardiovascular complications of T2DM. Our work focuses on one such complication that is specific for diabetes, named diabetic cardiomyopathy (DC). In this condition cardiac dysfunction occurs despite the absence of underlying hypertension, coronary artery disease and valvular disease, which suggest a leading role for metabolic disturbances as a cause. We aimed to establish the role of relatively new hypoglycaemic drugs that have taken the medical world by storm with their broad pleiotropic effects-SGLT-2 inhibitors-in the prevention and treatment of DC at any stage.

Citing Articles

Mechanistic insights and therapeutic potential of astilbin and apigenin in diabetic cardiomyopathy.

Dhiman S, Dhankhar S, Garg A, Rohilla M, Saini M, Singh T Heliyon. 2024; 10(21):e39996.

PMID: 39583813 PMC: 11582444. DOI: 10.1016/j.heliyon.2024.e39996.

Progress in the treatment of diabetic cardiomyopathy, a systematic review.

Shou Y, Li X, Fang Q, Xie A, Zhang Y, Fu X Pharmacol Res Perspect. 2024; 12(2):e1177.

PMID: 38407563 PMC: 10895687. DOI: 10.1002/prp2.1177.

The Therapeutic Potential of Targeting Ferroptosis in the Treatment of Mitochondrial Cardiomyopathies and Heart Failure.

Cantrell A, Zeng H, Chen J J Cardiovasc Pharmacol. 2023; 83(1):23-32.

PMID: 37816193 PMC: 10843296. DOI: 10.1097/FJC.0000000000001496.

Type 2 diabetes and in-hospital sudden cardiac arrest in ST-elevation myocardial infarction in the US.

Mhaimeed O, Pillai K, Dargham S, Suwaidi J, Jneid H, Abi Khalil C Front Cardiovasc Med. 2023; 10:1175731.

PMID: 37465457 PMC: 10351872. DOI: 10.3389/fcvm.2023.1175731.

References

Xing Y, Liu B, Wan S, Cheng Y, Zhou S, Sun Y . A SGLT2 Inhibitor Dapagliflozin Alleviates Diabetic Cardiomyopathy by Suppressing High Glucose-Induced Oxidative Stress and . Front Pharmacol. 2021; 12:708177. PMC: 8311522. DOI: 10.3389/fphar.2021.708177. View

. Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial. Nephrol Dial Transplant. 2022; 37(7):1317-1329. PMC: 9217655. DOI: 10.1093/ndt/gfac040. View

Rossing P, Inzucchi S, Vart P, Jongs N, Docherty K, Jhund P . Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. Lancet Diabetes Endocrinol. 2021; 10(1):24-34. DOI: 10.1016/S2213-8587(21)00295-3. View

Persson F, Nystrom T, Jorgensen M, Carstensen B, Gulseth H, Thuresson M . Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study. Diabetes Obes Metab. 2017; 20(2):344-351. PMC: 5811811. DOI: 10.1111/dom.13077. View

Garg S, Henry R, Banks P, Buse J, Davies M, Fulcher G . Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes. N Engl J Med. 2017; 377(24):2337-2348. DOI: 10.1056/NEJMoa1708337. View

Penpargkul S, Fein F, SONNENBLICK E, Scheuer J . Depressed cardiac sarcoplasmic reticular function from diabetic rats. J Mol Cell Cardiol. 1981; 13(3):303-9. DOI: 10.1016/0022-2828(81)90318-7. View

Pan G, Deshpande M, Pang H, Palaniyandi S . Precision medicine approach: Empagliflozin for diabetic cardiomyopathy in mice with aldehyde dehydrogenase (ALDH) 2 * 2 mutation, a specific genetic mutation in millions of East Asians. Eur J Pharmacol. 2018; 839:76-81. PMC: 7245698. DOI: 10.1016/j.ejphar.2018.09.021. View

Heidenreich P, Bozkurt B, Aguilar D, Allen L, Byun J, Colvin M . 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022; 145(18):e895-e1032. DOI: 10.1161/CIR.0000000000001063. View

Calapkulu M, Cander S, Gul O, Ersoy C . Lipid profile in type 2 diabetic patients with new dapagliflozin treatment; actual clinical experience data of six months retrospective lipid profile from single center. Diabetes Metab Syndr. 2019; 13(2):1031-1034. DOI: 10.1016/j.dsx.2019.01.016. View

10.

Blaschek W . Natural Products as Lead Compounds for Sodium Glucose Cotransporter (SGLT) Inhibitors. Planta Med. 2017; 83(12-13):985-993. DOI: 10.1055/s-0043-106050. View

11.

Bugger H, Abel E . Molecular mechanisms of diabetic cardiomyopathy. Diabetologia. 2014; 57(4):660-71. PMC: 3969857. DOI: 10.1007/s00125-014-3171-6. View

12.

Wiviott S, Raz I, Bonaca M, Mosenzon O, Kato E, Cahn A . Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2018; 380(4):347-357. DOI: 10.1056/NEJMoa1812389. View

13.

Dia M, Gomez L, Thibault H, Tessier N, Leon C, Chouabe C . Reduced reticulum-mitochondria Ca transfer is an early and reversible trigger of mitochondrial dysfunctions in diabetic cardiomyopathy. Basic Res Cardiol. 2020; 115(6):74. PMC: 7704523. DOI: 10.1007/s00395-020-00835-7. View

14.

Zhao Y, Xu L, Tian D, Xia P, Zheng H, Wang L . Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2017; 20(2):458-462. DOI: 10.1111/dom.13101. View

15.

Kamoshima H, Nomoto H, Yamashita K, Takahashi Y, Tsuchida K, Kuwabara S . Do the benefits of sodium-glucose cotransporter 2 inhibitors exceed the risks in patients with type 1 diabetes?. Endocr J. 2021; 69(5):495-509. DOI: 10.1507/endocrj.EJ21-0573. View

16.

Raghavan S, Vassy J, Ho Y, Song R, Gagnon D, Cho K . Diabetes Mellitus-Related All-Cause and Cardiovascular Mortality in a National Cohort of Adults. J Am Heart Assoc. 2019; 8(4):e011295. PMC: 6405678. DOI: 10.1161/JAHA.118.011295. View

17.

Seuring T, Archangelidi O, Suhrcke M . The Economic Costs of Type 2 Diabetes: A Global Systematic Review. Pharmacoeconomics. 2015; 33(8):811-31. PMC: 4519633. DOI: 10.1007/s40273-015-0268-9. View

18.

Kopp W . How Western Diet And Lifestyle Drive The Pandemic Of Obesity And Civilization Diseases. Diabetes Metab Syndr Obes. 2019; 12:2221-2236. PMC: 6817492. DOI: 10.2147/DMSO.S216791. View

19.

Salim H, Fukuda D, Yagi S, Soeki T, Shimabukuro M, Sata M . Glycemic Control with Ipragliflozin, a Novel Selective SGLT2 Inhibitor, Ameliorated Endothelial Dysfunction in Streptozotocin-Induced Diabetic Mouse. Front Cardiovasc Med. 2016; 3:43. PMC: 5080286. DOI: 10.3389/fcvm.2016.00043. View

20.

Moellmann J, Mann P, Kappel B, Kahles F, Klinkhammer B, Boor P . The sodium-glucose co-transporter-2 inhibitor ertugliflozin modifies the signature of cardiac substrate metabolism and reduces cardiac mTOR signalling, endoplasmic reticulum stress and apoptosis. Diabetes Obes Metab. 2022; 24(11):2263-2272. DOI: 10.1111/dom.14814. View